New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
08:59 EDTVCYTVeracyte shares well positioned in 2014, says Leerink
Leerink believes Veracyte shares are well positioned in 2014 with potential catalysts from additional positive coverage decisions and the launch of the Afirma malignant test. The firm raised its price target for shares to $21 from $17 and maintains an Outperform rating on the name.
News For VCYT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
07:32 EDTVCYTVeracyte partners with Pulmonary Fibrosis Foundation on lung disease survey
Veracyte and The Pulmonary Fibrosis Foundation are partnering on a U.S. patient survey to advance understanding of patients' diagnostic experiences with interstitial lung diseases, including idiopathic pulmonary fibrosis. The Interstitial Lung Disease Patient Journey survey will assess the steps and time required for patients to receive a diagnosis, specific obstacles hindering timely diagnosis, and the physical and emotional impact of patients' diagnostic journey.
August 24, 2015
08:29 EDTVCYTWilliam Blair to hold a field trip
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use